June 25th 2025
Marketed as Orlynvah, oral sulopenem from Iterum Therapeutics was FDA approved last fall for uncomplicated urinary tract infections and has shown efficacy against infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis.
Can COVID-19 Health Policy Inform How to Address Antimicrobial Resistance?
March 7th 2021While the world’s focus remains on COVID-19, beyond this ongoing crisis lingers another that requires leadership, innovation, and collaboration from policy makers, the health care community, and the private sector.
Watch
Discordant Empirical Antibiotic Therapy for Bloodstream Infections Ups Risk of Mortality
September 21st 2020About 1 in 5 patients with bloodstream infections received discordant empirical antibiotic therapy, increasing their risk of mortality independent of sepsis or septic shock, a new study found.
Read More